Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Targeted Antibiotic Drug Safest Among Recommended Treatments For Irritable Bowel Disease

02.11.2011
Among the most commonly used treatments for irritable bowel syndrome – which affects as many as 20 percent of the United States population – a targeted antibiotic was shown to be the safest in a new study by Cedars-Sinai researchers, based on an analysis of 26 large-scale clinical trials.

The study, for presentation at the American College of Gastroenterology annual meeting in Washington, D.C., examined drug interventions for IBS deemed to be of merit by a task force of the group . The study compared the therapies based on “number needed to harm statistics” from large clinical trials.

In evaluating a drug’s effectiveness, two common measures are the number needed to treat (the average number of patients who must take a therapy before one is treated successfully) and the number needed to harm (how many patients must be treated before the adverse effects of a therapy are bad enough that one patient drops the medication).

“For patients who suffer from irritable bowel syndrome, historically effective treatment options have been very scarce,” said Mark Pimentel, MD, director of the G.I. Motility Program at Cedars-Sinai Medical Center and a lead author on the study. “Unfortunately, many of the treatments approved for IBS cause intolerable complications for many patients. This underscores the need for us to continue to seek new therapies for this disease, which dramatically harms quality of life for millions of people.”

The study looked at the most common and highly rated treatments for the condition. Three of these treatments are for diarrhea-predominant IBS: tricyclic antidepressants; alosetron – a drug that slows movement of stool in the gut; and rifaximin, an antibiotic absorbed only in the gut. The difference among these drugs was striking. For tricyclic inhibitors, the number needed to harm was 18.3, while the number needed to harm for alosetron was 19.4. For rifaximin, the number needed to harm was 8,971.

The study also found that for every 2.3 and 2.6 patients who benefitted from tricyclic inhibitors and alosetron respectively, one patient was harmed by the study medication and had to withdraw. For rifaximin, this number was 897.

“This further validates previous research we’ve done on rifaximin as a safe and effective treatment for IBS,” Pimentel said. “Now, not only have our previous clinical studies shown that this selectively absorbed antibiotic is the first treatment for IBS patients in which patients continue to have relief from their symptoms after stopping the drug – compared to other available treatments for the condition, it statistically has caused fewer adverse side effects.”

In an article published earlier this year in the New England Journal of Medicine, the ground-breaking therapy developed at Cedars-Sinai found through two double-blind trials that patients who suffered from diarrhea prominent IBS reported relief from bloating, less abdominal pain and improved stool consistency for up to 10 weeks. While the concept of bacteria playing a key role in IBS was controversial when first unveiled a decade ago, this research confirms that bacteria in the gut trigger the symptoms of the chronic condition, affecting an estimated 30 million people in the United States.

Rifaximin is marketed by Salix Pharmaceuticals Inc. Pimentel discovered the use of rifaximin for IBS, and Cedars-Sinai holds patent rights to this discovery and has licensed rights to the invention to Salix. Dr. Pimentel is a consultant to Salix Inc, and serves on its scientific advisory board.

Nicole White | Cedars-Sinai News
Further information:
http://www.cshs.org

Further reports about: Disease Drug Delivery IBS Recommended Safest antibiotic bowel effective treatment targeted treatments

More articles from Studies and Analyses:

nachricht Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>